The efficacy and safety of dual orexin receptor antagonists in primary insomnia: A systematic review and network meta-analysis.

  title={The efficacy and safety of dual orexin receptor antagonists in primary insomnia: A systematic review and network meta-analysis.},
  author={Tao Xue and Xin Wu and Shujun Chen and Yanbo Yang and Zeya Yan and Zhaoming Song and Wei Zhang and Jianguo Zhang and Zhouqing Chen and Zhong Wang},
  journal={Sleep medicine reviews},

Orexin Receptor Antagonists and Insomnia

We review recent evidence on the use of orexin receptor antagonists (ORAs) for treating insomnia. We evaluate studies on five dual ORAs and one selective ORA. Research on suvorexant in recent years

Improved Functional Organization in Patients With Primary Insomnia After Individually-Targeted Transcranial Magnetic Stimulation

Primary insomnia (PI) is among the most prevalent sleep-related disorders and has a far-reaching impact on daytime functioning. Repetitive transcranial magnetic stimulation (rTMS) has drawn attention

Common Sleep Disorders in Pregnancy

Important considerations are outlined for obstetricians taking care of pregnant patients with sleep-related complaints because sleep disruption in pregnancy can substantially worsen maternal quality of life and may be a risk factor for adverse pregnancy outcomes.

Major advances in sleep neurology: 2002–22



Dual Orexin Receptor Antagonist, Almorexant, in Elderly Patients With Primary Insomnia: A Randomized, Controlled Study

Two‐night oral administration of almorexant was effective and well tolerated in treating primary insomnia in elderly patients, and no unexpected safety concerns were identified.

Orexin Receptor Antagonism, a New Sleep-Enabling Paradigm: A Proof-of-Concept Clinical Trial

Almorexant consistently and dose‐dependently improved sleep variables and may offer a new treatment approach for primary insomnia.

Orexin receptor antagonism for treatment of insomnia

The data suggest that orexin receptor antagonism offers a novel approach to treating insomnia, and Class I evidence that suvorexant improves sleep efficiency over 4 weeks in nonelderly adult patients with primary insomnia.

A randomized Phase 2 study to evaluate the orexin-2 receptor antagonist seltorexant in individuals with insomnia without psychiatric comorbidity

Investigation of the effect of seltorexant on sleep efficiency after single and multiple dose administration in subjects with insomnia disorder without psychiatric comorbidity resulted in a prolonged total sleep time, shorter latency to persistent sleep and wake after sleep onset.

A Phase II Dose-Ranging Study Evaluating the Efficacy and Safety of the Orexin Receptor Antagonist Filorexant (MK-6096) in Patients with Primary Insomnia

Orexin receptor antagonism by filorexant significantly improved sleep efficiency in nonelderly patients with insomnia and was generally well tolerated.

Randomized controlled trial of the orexin receptor antagonist filorexant for migraine prophylaxis

Data fail to provide evidence that antagonism of orexin receptors with filorexant, when administered at night, is effective for migraine prophylaxis.

The selective orexin-2 receptor antagonist seltorexant improves sleep: An exploratory double-blind, placebo controlled, crossover study in antidepressant-treated major depressive disorder patients with persistent insomnia

Seltorexant showed a statistically significant, dose-dependent decrease in latency to persistent sleep, and increase in total sleep time and sleep efficiency combined with a tendency toward subjectively improved mood.

Long-term efficacy and tolerability of lemborexant compared with placebo in adults with insomnia disorder: results from the phase 3 randomized clinical trial SUNRISE 2

LEM5 and LEM10 provided significant benefit on sleep onset and sleep maintenance in individuals with insomnia disorder versus placebo, and was well tolerated.